IN2014DN07082A - - Google Patents
Info
- Publication number
- IN2014DN07082A IN2014DN07082A IN7082DEN2014A IN2014DN07082A IN 2014DN07082 A IN2014DN07082 A IN 2014DN07082A IN 7082DEN2014 A IN7082DEN2014 A IN 7082DEN2014A IN 2014DN07082 A IN2014DN07082 A IN 2014DN07082A
- Authority
- IN
- India
- Prior art keywords
- alkyl
- dibenzoyltartrate
- haloalkyl
- cycloalkyl
- chloride
- Prior art date
Links
- OCQAXYHNMWVLRH-UHFFFAOYSA-N 2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(O)(C(O)=O)C(O)(C(=O)O)C(=O)C1=CC=CC=C1 OCQAXYHNMWVLRH-UHFFFAOYSA-N 0.000 abstract 1
- 102000004499 CCR3 Receptors Human genes 0.000 abstract 1
- 108010017316 CCR3 Receptors Proteins 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 150000001450 anions Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
THE PRESENT INVENTION RELATES TO PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF FORMULA (1) WHEREIN R IS H C ALKYL C ALKYL C CYCLOALKYL C HALOALKYL; R IS H C ALKYL; X IS AN ANION SELECTED FROM THE GROUP CONSISTING OF CHLORIDE OR ½ DIBENZOYLTARTRATE J IS 1 OR 2. PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE TO TREAT DISEASES CONNECTED WITH THE CCR3 RECEPTOR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163078 | 2012-04-04 | ||
| PCT/EP2013/056867 WO2013149987A1 (en) | 2012-04-04 | 2013-04-02 | Pharmaceutical formulations comprising ccr3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07082A true IN2014DN07082A (en) | 2015-04-10 |
Family
ID=49292482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7082DEN2014 IN2014DN07082A (en) | 2012-04-04 | 2013-04-02 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10213421B2 (en) |
| EP (3) | EP2833864B1 (en) |
| JP (4) | JP6320990B2 (en) |
| KR (2) | KR102138709B1 (en) |
| CN (1) | CN104203213A (en) |
| AR (1) | AR090596A1 (en) |
| AU (1) | AU2013245028B2 (en) |
| BR (1) | BR112014024479A8 (en) |
| CA (1) | CA2869058C (en) |
| CL (1) | CL2014002524A1 (en) |
| CY (1) | CY1121137T1 (en) |
| DK (2) | DK3524230T3 (en) |
| EA (1) | EA027627B1 (en) |
| ES (3) | ES3044310T3 (en) |
| HR (1) | HRP20190069T1 (en) |
| HU (2) | HUE056943T2 (en) |
| IL (1) | IL234299A (en) |
| IN (1) | IN2014DN07082A (en) |
| LT (1) | LT2833864T (en) |
| MX (1) | MX358307B (en) |
| NZ (1) | NZ628993A (en) |
| PH (1) | PH12014502241A1 (en) |
| PL (2) | PL3524230T3 (en) |
| PT (2) | PT2833864T (en) |
| RS (1) | RS58360B1 (en) |
| SI (1) | SI2833864T1 (en) |
| SM (1) | SMT201900121T1 (en) |
| TR (1) | TR201821285T4 (en) |
| TW (1) | TW201400115A (en) |
| UY (1) | UY34730A (en) |
| WO (1) | WO2013149987A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (en) | 2010-10-07 | 2015-08-10 | Common Crystals and Salts of CCR3 Inhibitors | |
| AR090566A1 (en) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | PROCESS FOR THE PRODUCTION OF CRR INHIBITORS |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| ES3046717T3 (en) | 2017-04-05 | 2025-12-02 | Alkahest Inc | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
| EP3606525B1 (en) | 2017-04-05 | 2025-12-10 | Alkahest, Inc. | Compositions for treating aging-associated impairments using ccr3-inhibitors |
| CN111343983A (en) * | 2017-10-13 | 2020-06-26 | 万能溶剂有限公司 | Methods and compositions for treating pruritus, xerosis and related diseases using CCR3 inhibitors |
| BR112020023001A2 (en) | 2018-05-15 | 2021-02-02 | Alkahest, Inc. | treatment of disease associated with aging with leukotriene a4 hydrolase modulators |
| JP7528065B2 (en) * | 2018-09-26 | 2024-08-05 | アルカヘスト，インコーポレイテッド | Methods and compositions for treating age-related dysfunction using CCR3 inhibitors |
| CA3180401A1 (en) | 2020-06-11 | 2021-12-16 | Bartosz SIKORSKI | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| KR20230056017A (en) | 2020-08-27 | 2023-04-26 | 에이지씨 가부시키가이샤 | Alkali-free glass and glass plates |
| EP4426284A4 (en) | 2021-11-01 | 2025-11-12 | Alkahest Inc | BENZODIOXINE MODULATORS OF LEUKOTRIEN A4 HYDROLASE (LTA4H) FOR THE PREVENTION AND TREATMENT OF AGE-RELATED DISEASES |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7907121L (en) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | FTALIMIDINDERIVAT |
| US4992277A (en) | 1989-08-25 | 1991-02-12 | Schering Corporation | Immediate release diltiazem formulation |
| JP2807577B2 (en) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | Cyclic amide derivative |
| IL116539A (en) * | 1995-01-06 | 2002-02-10 | Noven Pharma | Compositions for transdermal delivery of acid-labile drugs |
| KR20010012402A (en) * | 1997-05-09 | 2001-02-15 | 세이지 파마슈티칼스, 인크. | Stable oral pharmaceutical dosage forms |
| WO1999037619A1 (en) | 1998-01-21 | 1999-07-29 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| EP1052992A1 (en) | 1998-02-02 | 2000-11-22 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| SE9802973D0 (en) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2004004716A1 (en) * | 2002-07-08 | 2004-01-15 | Chemgenex Pharmaceuticals Limited | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
| EP1668035A2 (en) | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| CN1871222A (en) | 2003-10-24 | 2006-11-29 | 霍夫曼-拉罗奇有限公司 | CCR3 receptor antagonists |
| KR20060127000A (en) | 2003-11-17 | 2006-12-11 | 베링거 인겔하임 인터내셔날 게엠베하 | Novel piperidine-substituted indole derivatives or their use as heteromodulators and modulators of chemokine receptors (CCR-3) |
| CN1946402A (en) | 2004-02-05 | 2007-04-11 | 先灵公司 | Piperdine derivatives useful as CCR3 antagonists |
| JP2006137718A (en) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | Indole or indazole derivatives |
| WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| DOP2006000051A (en) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | VEGF-R2 INHIBITORS AND METHODS |
| JP3701964B1 (en) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | Novel salts of quinuclidine derivatives |
| WO2006117314A2 (en) | 2005-04-30 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Novel piperidin- substituted indoles and their use as ccr-3 modulators |
| NL2000323C2 (en) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine derivatives. |
| US20090124636A1 (en) | 2006-04-12 | 2009-05-14 | Pfizer Inc. | Chemical compounds |
| ATE524461T1 (en) | 2006-10-27 | 2011-09-15 | Boehringer Ingelheim Int | NEW SUBSTITUTED PIPERIDYLPROPANTHIOLE |
| CA2667547C (en) | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| JP2011500780A (en) | 2007-10-24 | 2011-01-06 | ジェネリクス・（ユーケー）・リミテッド | New crystal form |
| TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2010052727A1 (en) * | 2008-11-04 | 2010-05-14 | Ideal Cures Private Limited | High performance film coating compositions |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| SG175748A1 (en) * | 2009-04-22 | 2011-12-29 | Axikin Pharmaceuticals Inc | 2,5-disubstituted arylsulfonamide ccr3 antagonists |
| PE20120810A1 (en) | 2009-04-22 | 2012-07-08 | Axikin Pharmaceuticals Inc | COMPOUNDS DERIVED FROM 5-CYANE-2- (PHENYLTHIUM) BENCENSULFONAMIDE AS ANTAGONISTS OF CCR3 |
| EP2523654A4 (en) * | 2010-01-11 | 2014-08-06 | Mohamed Shafee Muneera | Immediate release compositions of acid labile drugs |
| UA109290C2 (en) | 2010-10-07 | 2015-08-10 | Common Crystals and Salts of CCR3 Inhibitors | |
| AR090566A1 (en) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | PROCESS FOR THE PRODUCTION OF CRR INHIBITORS |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2013
- 2013-03-27 US US13/851,538 patent/US10213421B2/en active Active
- 2013-04-02 ES ES21190323T patent/ES3044310T3/en active Active
- 2013-04-02 KR KR1020147027802A patent/KR102138709B1/en active Active
- 2013-04-02 EA EA201401082A patent/EA027627B1/en not_active IP Right Cessation
- 2013-04-02 PT PT13714618T patent/PT2833864T/en unknown
- 2013-04-02 LT LTEP13714618.9T patent/LT2833864T/en unknown
- 2013-04-02 PL PL18213458T patent/PL3524230T3/en unknown
- 2013-04-02 PL PL13714618T patent/PL2833864T3/en unknown
- 2013-04-02 HR HRP20190069TT patent/HRP20190069T1/en unknown
- 2013-04-02 CN CN201380016781.7A patent/CN104203213A/en active Pending
- 2013-04-02 NZ NZ628993A patent/NZ628993A/en unknown
- 2013-04-02 JP JP2015503848A patent/JP6320990B2/en active Active
- 2013-04-02 TR TR2018/21285T patent/TR201821285T4/en unknown
- 2013-04-02 WO PCT/EP2013/056867 patent/WO2013149987A1/en not_active Ceased
- 2013-04-02 EP EP13714618.9A patent/EP2833864B1/en active Active
- 2013-04-02 CA CA2869058A patent/CA2869058C/en active Active
- 2013-04-02 HU HUE18213458A patent/HUE056943T2/en unknown
- 2013-04-02 RS RS20190050A patent/RS58360B1/en unknown
- 2013-04-02 EP EP18213458.5A patent/EP3524230B1/en active Active
- 2013-04-02 SI SI201331330T patent/SI2833864T1/en unknown
- 2013-04-02 EP EP21190323.2A patent/EP3970693B1/en active Active
- 2013-04-02 AU AU2013245028A patent/AU2013245028B2/en active Active
- 2013-04-02 DK DK18213458.5T patent/DK3524230T3/en active
- 2013-04-02 PT PT182134585T patent/PT3524230T/en unknown
- 2013-04-02 HU HUE13714618A patent/HUE041519T2/en unknown
- 2013-04-02 MX MX2014011787A patent/MX358307B/en active IP Right Grant
- 2013-04-02 DK DK13714618.9T patent/DK2833864T3/en active
- 2013-04-02 BR BR112014024479A patent/BR112014024479A8/en not_active Application Discontinuation
- 2013-04-02 KR KR1020207021307A patent/KR102338465B1/en active Active
- 2013-04-02 ES ES18213458T patent/ES2898179T3/en active Active
- 2013-04-02 IN IN7082DEN2014 patent/IN2014DN07082A/en unknown
- 2013-04-02 SM SM20190121T patent/SMT201900121T1/en unknown
- 2013-04-02 ES ES13714618T patent/ES2715844T3/en active Active
- 2013-04-03 TW TW102112244A patent/TW201400115A/en unknown
- 2013-04-03 AR ARP130101093A patent/AR090596A1/en unknown
- 2013-04-04 UY UY0001034730A patent/UY34730A/en unknown
-
2014
- 2014-08-26 IL IL234299A patent/IL234299A/en active IP Right Grant
- 2014-09-24 CL CL2014002524A patent/CL2014002524A1/en unknown
- 2014-10-03 PH PH12014502241A patent/PH12014502241A1/en unknown
-
2018
- 2018-04-04 JP JP2018072309A patent/JP6700332B2/en active Active
- 2018-12-28 US US16/235,905 patent/US20190151300A1/en not_active Abandoned
-
2019
- 2019-01-17 CY CY20191100062T patent/CY1121137T1/en unknown
-
2020
- 2020-04-29 US US16/861,473 patent/US11612596B2/en active Active
- 2020-04-30 JP JP2020080024A patent/JP2020143080A/en active Pending
-
2022
- 2022-02-24 JP JP2022026735A patent/JP2022081524A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502241A1 (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| IN2014MN02459A (en) | ||
| MX2015017861A (en) | Benzothiophene derivatives as estrogen receptor inhibitors. | |
| PH12014502524A1 (en) | Carboxylic acid compounds | |
| EA033343B1 (en) | Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| MD4496B1 (en) | 2'-Substituted carba-nucleoside analogs for antiviral treatment | |
| SG190785A1 (en) | Antiviral compounds | |
| GEP20166438B (en) | Imidazopyrrolidinone compounds | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| IN2014MN00697A (en) | ||
| MX2013012652A (en) | Derivatives of n- [(1h-pyrazol-1-yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists. | |
| IN2015DN00957A (en) | ||
| GEP201706621B (en) | Benzamides | |
| MX342924B (en) | Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases. | |
| MX2016007128A (en) | Ccr6 compounds. | |
| MX2014004858A (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies. | |
| MX2014006433A (en) | Novel 2h-indazoles as ep2 receptor antagonists. | |
| PH12014502285A1 (en) | Anti-malarial agents | |
| IN2014KN00849A (en) | ||
| MX2015005312A (en) | 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists. | |
| MY168750A (en) | Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists | |
| MA37879B1 (en) | Stabilized amorphous form of agomelatine, process for its preparation and pharmaceutical compositions containing it | |
| IN2014KN00847A (en) | ||
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |